Contrasting Aquestive Therapeutics (NASDAQ:AQST) & Verrica Pharmaceuticals (NASDAQ:VRCA)

Aquestive Therapeutics (NASDAQ:AQST) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Profitability

This table compares Aquestive Therapeutics and Verrica Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

Institutional and Insider Ownership

32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 6.8% of Aquestive Therapeutics shares are owned by insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Aquestive Therapeutics and Verrica Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54 million	12.48	-$83.78 million	($0.61)	-7.26
Verrica Pharmaceuticals	$35.58 million	2.82	-$17.89 million	($1.03)	-5.66

Verrica Pharmaceuticals has lower revenue, but higher earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Aquestive Therapeutics has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Aquestive Therapeutics and Verrica Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1	0	4	2	3.00
Verrica Pharmaceuticals	1	1	2	0	2.25

Aquestive Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 91.87%. Verrica Pharmaceuticals has a consensus price target of $14.50, indicating a potential upside of 148.71%. Given Verrica Pharmaceuticals’ higher possible upside, analysts plainly believe Verrica Pharmaceuticals is more favorable than Aquestive Therapeutics.

Summary

Verrica Pharmaceuticals beats Aquestive Therapeutics on 8 of the 15 factors compared between the two stocks.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.